Stocktoria
Biofrontera Inc. BFRI
Biofrontera Inc. (BFRI) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $41.7M at a -25.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.217 |
| Retained earnings / assets | -4.479 |
| EBIT / assets | -0.397 |
| Equity / liabilities | 0.58 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BFRI | Biofrontera Inc. | 1/9 | -15.24 | — | +11.7% |
| WVE | Wave Life Sciences Ltd. | 2/9 | 1.15 | — | -60.5% |
| XLO | Xilio Therapeutics, Inc. | 4/9 | -6.58 | — | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | 4/9 | -0.86 | — | +17.6% |
| AQST | Aquestive Therapeutics, Inc. | 2/9 | -8.08 | — | -22.6% |
| BGM | BGM Group Ltd. | 5/9 | 7.99 | — | +51.1% |
| SEPN | Septerna, Inc. | 4/9 | 3.75 | — | — |
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
FAQ
Is BFRI financially healthy?
Biofrontera Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does BFRI pay a dividend?
No, Biofrontera Inc. does not currently pay a dividend.
How profitable is BFRI?
In FY2025, Biofrontera Inc. had a net margin of -25.3% and a return on equity of -100.5%.
What is the analyst price target for BFRI?
The average Wall-Street price target for Biofrontera Inc. is $5.88, about 370.0% above the recent price, from 2 analysts.
Is BFRI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Biofrontera Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.